Senior Data Scientist: Medical Imaging
About the job
- A PhD in Computer Science, Biomedical Engineering, Medical Physics, or a related field, with a focus on medical imaging.
- At least 5 years of post-PhD industry experience developing production-grade artificial intelligence models for medical imaging applications.
- Deep expertise in computer vision and deep learning architectures, including convolutional neural networks, U-Net, and Vision Transformers, for medical image analysis.
- A proven track record with MRI and X-ray image analysis, including hands-on experience with DICOM standards and medical imaging software.
- Strong programming skills in Python, with expertise in PyTorch or TensorFlow and medical imaging libraries.
- Ability to collaborate with radiologists and clinical teams to translate medical insights into technical solutions.
- Ability to present complex imaging analytics to diverse stakeholders.
- Lead the development of advanced deep learning models for medical image analysis, focusing on MRI and X-ray modalities for clinical trial applications.
- Design and implement automated image processing pipelines for disease detection, segmentation, and quantification across multiple therapeutic areas.
- Create approaches for longitudinal image analysis to track disease progression and treatment efficacy in clinical trials, including artificial-intelligence-based biomarkers and surrogate endpoints.
- Collaborate with clinical operations to integrate imaging artificial intelligence solutions into trial protocols and workflows.
- Partner with regulatory teams to ensure imaging biomarkers and artificial intelligence models meet Food and Drug Administration standards for clinical trial endpoints.
- Build scalable infrastructure for processing and analyzing large-scale medical imaging datasets from multi-site clinical trials.
- Present imaging insights and model performance to executive leadership and external partners.
- Experience with regulatory submissions involving imaging endpoints or artificial-intelligence-based image analysis tools.
- Experience with multi-modal imaging fusion and analysis, combining MRI, CT, and PET data.
- Knowledge of clinical trial design and experience with imaging core lab operations.
- Experience with federated learning or privacy-preserving techniques for medical imaging.
- Understanding of radiomics and quantitative imaging biomarker development.
- Experience with 3D image reconstruction and volumetric analysis.
About the company
Formation Bio uses an AI-driven platform to speed up drug development by focusing on clinical-stage assets. It acquires and advances these assets using flexible financing structures, aiming to shorten timelines and cut costs for bringing new drugs to market. The core product is the proprietary AI tools that help with drug selection, development planning, and improving overall efficiency, enabling partnerships and successful commercialization with pharmaceutical and biotech companies. Compared with competitors, Formation Bio combines a data-powered approach with adaptable financing and asset acquisition strategies to move assets forward quickly and cost-effectively. The goal is to make treatments more accessible and affordable by accelerating development and enabling faster, more predictable commercialization through AI-enhanced decision making and flexible funding options.
Company Size
51-200
Company Stage
Series D
Total Funding
$530.3M
Headquarters
New York City, New York
Founded
2013
Get referred to Formation Bio
See people who can refer or advise you
Simplify's Take
What believers are saying
- January 29, 2026 Kenmare Bio in-licensed FHND5032, expanding autoimmune pipeline depth.
- June 9, 2026 BLKR201 dosing created a near-term early-2027 catalyst.
- Formation Bio raised $372 million in Series D, supporting pipeline and AI expansion.
What critics are saying
- BLKR201 remains unproven; early-2027 readout determines whether Formation Bio justifies its model.
- FHND5032 and BLKR201 concentrate value in two assets; one failure crushes leverage.
- Without repeat clinical wins, Formation Bio becomes a costly AI wrapper around failed bets.
What makes Formation Bio unique
- Formation Bio pairs AI software with clinical asset ownership, not pure-platform licensing.
- July 22, 2026 hire Michael Ehlers strengthens translational and clinical development credibility.
- June 9, 2026 BLKR201 entered Phase 1 five months after in-licensing.
Help us improve and share your feedback! Did you find this helpful?
Benefits
- Company Equity
- Remote Work Options
- Flexible Work Hours